Australie - anglais - Department of Health (Therapeutic Goods Administration)

sax health care pty ltd - 36282 - contraceptive, condom, male - a latex male condom that is lubnricated (non-spermicidal) used to help reduce the risk of sexually transmitted diseases and also pregnancy

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sayco pty ltd - 35237 - contraceptive, pessary - vaginal pessaries for supporting pelvic organs for prolapse and stress incontinence

Australie - anglais - Department of Health (Therapeutic Goods Administration)

advantage health care pty limited - 35237 - contraceptive, pessary - device used to support the pelvic organs to relieve the incidence of stress incontinence. not to be used for controceptive purposes.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

bliss grip - 43940 - contraceptive, condom, - a sheath or cover, worn by a male, to provide a physical barrier between the penis and the vagina during coitus in order to prevent conception and disease transmission. the device is made of a natural rubber latex contains a spermicidal lubricant. the is a single-use device that may also be used to collect semen to aid in the diagnosis of infertility.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

smiths medical australasia pty ltd - 47260 - contrast medium injection system hand controller kit - the device is to be used to deliver intravenous solutions to the site of the infusion, and comprises of various style chambers, needles, tubing lengths, clamps and connectors.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 36968 - contrast medium injector system, control unit - intended to remotely control the injector.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

gytech pty ltd - 40726 - contrast medium, ultrasound, - to be used to temporarily distend the uterus and fallopian tubes to facilitate visualisation using ultrasound imaging. it is intended to enable or enhance the capability of an ultrasound imaging system to detect and visualise various body structures in order to allow persons interpreting ultrasound images and data to differentiate between normal and pathological conditions.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - 47259 - contrast medium injection system syringe - this device is intended for the injection of contrast media and saline, and compatible only with guerbet optivantage injectors and manyfill set product. the device is intended for multi-patient use up to 12/24 hours, no reprocessing allowed.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - citalopram hydrobromide 49.96mg equivalent to to 40 mg citralopram - film coated tablet - 40 mg - active: citalopram hydrobromide 49.96mg equivalent to to 40 mg citralopram excipient: croscarmellose sodium glycerol hypromellose e-5 lactose monohydrate macrogol 400 magnesium stearate maize starch microcrystalline cellulose povidone titanium dioxide

États-Unis - anglais - NLM (National Library of Medicine)

doh central pharmacy - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline primary protease inhibitor mutations affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for therapy-experienced adult patients or any pediatric patients. ● kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. ●  co-administration of kaletra is contraindicated with drugs t